[{"address1": "1700 Owens Street", "address2": "Suite 205", "city": "San Francisco", "state": "CA", "zip": "94158", "country": "United States", "phone": "415 660 5320", "fax": "415 525 4200", "website": "https://www.nurixtx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.", "fullTimeEmployees": 284, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arthur T. Sands M.D., Ph.D.", "age": 61, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 986321, "exercisedValue": 0, "unexercisedValue": 1089996}, {"maxAge": 1, "name": "Mr. Johannes  Van Houte", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 681983, "exercisedValue": 0, "unexercisedValue": 133109}, {"maxAge": 1, "name": "Dr. Gwenn M. Hansen Ph.D.", "age": 52, "title": "Chief Scientific Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 702753, "exercisedValue": 0, "unexercisedValue": 591867}, {"maxAge": 1, "name": "Dr. John  Kuriyan Ph.D.", "title": "Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Rap\u00e9 Ph.D.", "title": "Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arthur  Weiss M.D., Ph.D.", "title": "Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Rita  Kwong", "title": "Senior Accounting Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pasit  Phiasivongsa Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christine  Ring J.D., Ph.D.", "age": 58, "title": "Chief Legal Officer, Secretary & Chief Compliance Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 595830, "exercisedValue": 599893, "unexercisedValue": 5469113}, {"maxAge": 1, "name": "Mr. Eric C. Schlezinger J.D.", "age": 56, "title": "Chief People Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 25.44, "open": 25.68, "dayLow": 24.6, "dayHigh": 25.705, "regularMarketPreviousClose": 25.44, "regularMarketOpen": 25.68, "regularMarketDayLow": 24.6, "regularMarketDayHigh": 25.705, "beta": 2.233, "forwardPE": -8.963899, "volume": 502229, "regularMarketVolume": 502229, "averageVolume": 820916, "averageVolume10days": 458190, "averageDailyVolume10Day": 458190, "bid": 24.79, "ask": 24.89, "bidSize": 100, "askSize": 200, "marketCap": 1599347456, "fiftyTwoWeekLow": 4.22, "fiftyTwoWeekHigh": 26.123, "priceToSalesTrailing12Months": 25.670473, "fiftyDayAverage": 22.6037, "twoHundredDayAverage": 15.18575, "currency": "USD", "enterpriseValue": 1224317952, "profitMargins": -2.64838, "floatShares": 50881513, "sharesOutstanding": 64411900, "sharesShort": 9261820, "sharesShortPriorMonth": 9321186, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.1438, "heldPercentInsiders": 0.01871, "heldPercentInstitutions": 1.04276, "shortRatio": 15.25, "shortPercentOfFloat": 0.1554, "bookValue": 5.76, "priceToBook": 4.310764, "lastFiscalYearEnd": 1701302400, "nextFiscalYearEnd": 1732924800, "mostRecentQuarter": 1717113600, "netIncomeToCommon": -165002000, "trailingEps": -2.92, "forwardEps": -2.77, "enterpriseToRevenue": 19.651, "enterpriseToEbitda": -7.108, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NRIX", "underlyingSymbol": "NRIX", "shortName": "Nurix Therapeutics, Inc.", "longName": "Nurix Therapeutics, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "961e16e7-4ed3-306e-9661-e0e70ede1cf2", "gmtOffSetMilliseconds": -14400000, "currentPrice": 24.83, "targetHighPrice": 36.0, "targetLowPrice": 15.0, "targetMeanPrice": 29.0, "targetMedianPrice": 30.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 443139008, "totalCashPerShare": 6.88, "ebitda": -172244992, "totalDebt": 28819000, "quickRatio": 5.493, "currentRatio": 5.573, "totalRevenue": 62303000, "debtToEquity": 7.774, "revenuePerShare": 1.101, "returnOnAssets": -0.25983, "returnOnEquity": -0.52331, "freeCashflow": -65623624, "operatingCashflow": -96100000, "revenueGrowth": -0.606, "grossMargins": -2.1538801, "ebitdaMargins": -2.76463, "operatingMargins": -4.0142198, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-17"}]